Conmed (CNMD) reported $321.26 million in revenue for the quarter ended March 2025, representing a year-over-year increase of 2.9%. EPS of $0.95 for the same period compares to $0.79 a year ago.
The reported revenue represents a surprise of +2.42% over the Zacks Consensus Estimate of $313.68 million. With the consensus EPS estimate being $0.81, the EPS surprise was +17.28%.
While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.
As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.
Here is how Conmed performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Geographic Revenue- Domestic: $183.80 million versus the two-analyst average estimate of $175.66 million. The reported number represents a year-over-year change of +4.2%.
- Geographic Revenue- International: $137.50 million compared to the $138.31 million average estimate based on two analysts. The reported number represents a change of +1.2% year over year.
- Net Sales- Orthopedic Surgery: $138.30 million compared to the $125.60 million average estimate based on three analysts. The reported number represents a change of +2.5% year over year.
- Net Sales- General Surgery: $183 million compared to the $182.04 million average estimate based on three analysts. The reported number represents a change of +3.2% year over year.
- Net Sales- Single-use Products: $276.30 million versus the two-analyst average estimate of $268.71 million. The reported number represents a year-over-year change of +4.4%.
- Net Sales- Capital Products: $45 million compared to the $45.25 million average estimate based on two analysts. The reported number represents a change of -5.5% year over year.
View all Key Company Metrics for Conmed here>>>
Shares of Conmed have returned -13.9% over the past month versus the Zacks S&P 500 composite's -0.2% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
CONMED Corporation (CNMD): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
